AU2014284235C1 - Methods for treating nasal polyposis by administering an IL-4R antagonist - Google Patents

Methods for treating nasal polyposis by administering an IL-4R antagonist

Info

Publication number
AU2014284235C1
AU2014284235C1 AU2014284235A AU2014284235A AU2014284235C1 AU 2014284235 C1 AU2014284235 C1 AU 2014284235C1 AU 2014284235 A AU2014284235 A AU 2014284235A AU 2014284235 A AU2014284235 A AU 2014284235A AU 2014284235 C1 AU2014284235 C1 AU 2014284235C1
Authority
AU
Australia
Prior art keywords
antibody
binding fragment
antigen binding
nasal
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014284235A
Other languages
English (en)
Other versions
AU2014284235A1 (en
AU2014284235B2 (en
Inventor
Robert Evans
Namita A. Gandhi
Leda MANNENT
Gianluca Pirozzi
Allen Radin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50736018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014284235(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of AU2014284235A1 publication Critical patent/AU2014284235A1/en
Priority to AU2019261751A priority Critical patent/AU2019261751B2/en
Application granted granted Critical
Publication of AU2014284235B2 publication Critical patent/AU2014284235B2/en
Priority to AU2022201336A priority patent/AU2022201336B2/en
Priority to AU2025205430A priority patent/AU2025205430A1/en
Publication of AU2014284235C1 publication Critical patent/AU2014284235C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2014284235A 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an IL-4R antagonist Active AU2014284235C1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2019261751A AU2019261751B2 (en) 2013-06-21 2019-11-07 Methods for treating nasal polyposis by administering an IL-4R antagonist
AU2022201336A AU2022201336B2 (en) 2013-06-21 2022-02-25 Methods for treating nasal polyposis by administering an IL-4R antagonist
AU2025205430A AU2025205430A1 (en) 2013-06-21 2025-07-14 Methods for treating nasal polyposis by administering an IL-4R antagonist

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361837912P 2013-06-21 2013-06-21
US61/837,912 2013-06-21
EP14305670 2014-05-07
EP14305670.3 2014-05-07
PCT/US2014/043440 WO2014205365A1 (en) 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an il-4r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019261751A Division AU2019261751B2 (en) 2013-06-21 2019-11-07 Methods for treating nasal polyposis by administering an IL-4R antagonist

Publications (3)

Publication Number Publication Date
AU2014284235A1 AU2014284235A1 (en) 2016-01-21
AU2014284235B2 AU2014284235B2 (en) 2019-11-21
AU2014284235C1 true AU2014284235C1 (en) 2025-07-31

Family

ID=50736018

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2014284235A Active AU2014284235C1 (en) 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an IL-4R antagonist
AU2019261751A Active AU2019261751B2 (en) 2013-06-21 2019-11-07 Methods for treating nasal polyposis by administering an IL-4R antagonist
AU2022201336A Active AU2022201336B2 (en) 2013-06-21 2022-02-25 Methods for treating nasal polyposis by administering an IL-4R antagonist
AU2025205430A Pending AU2025205430A1 (en) 2013-06-21 2025-07-14 Methods for treating nasal polyposis by administering an IL-4R antagonist

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2019261751A Active AU2019261751B2 (en) 2013-06-21 2019-11-07 Methods for treating nasal polyposis by administering an IL-4R antagonist
AU2022201336A Active AU2022201336B2 (en) 2013-06-21 2022-02-25 Methods for treating nasal polyposis by administering an IL-4R antagonist
AU2025205430A Pending AU2025205430A1 (en) 2013-06-21 2025-07-14 Methods for treating nasal polyposis by administering an IL-4R antagonist

Country Status (20)

Country Link
US (1) US10059771B2 (enExample)
EP (3) EP3010539B1 (enExample)
JP (1) JP6463351B2 (enExample)
KR (4) KR20230066127A (enExample)
CN (2) CN111437387B (enExample)
AU (4) AU2014284235C1 (enExample)
CA (1) CA2915839A1 (enExample)
CY (1) CY1122754T1 (enExample)
ES (1) ES3050809T3 (enExample)
HU (1) HUE073368T2 (enExample)
IL (1) IL243246B (enExample)
MX (1) MX368068B (enExample)
PL (2) PL3613432T3 (enExample)
PT (1) PT3613432T (enExample)
RS (1) RS59354B1 (enExample)
RU (1) RU2674680C2 (enExample)
SG (2) SG10201710557QA (enExample)
SI (1) SI3010539T1 (enExample)
TW (2) TWI709411B (enExample)
WO (1) WO2014205365A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
RS59354B1 (sr) 2013-06-21 2019-10-31 Sanofi Biotechnology Postupci lečenja nosne polipoze davanjem il-4r antagonista
HRP20191709T1 (hr) * 2013-06-21 2019-12-13 Sanofi Biotechnology Postupci liječenja nosne polipoze davanjem antagonista il-4r
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
CA3246946A1 (en) * 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
EP3416685B1 (en) * 2016-02-19 2024-06-26 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
KR102872485B1 (ko) * 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
CN108339118A (zh) * 2017-01-23 2018-07-31 瑞阳(苏州)生物科技有限公司 治疗或预防阻塞性睡眠呼吸暂停的药物组合物
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
US11034768B2 (en) 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CN111494626B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
CA3124670A1 (en) 2018-12-28 2020-07-02 Regeneron Pharmaceuticals, Inc. Treatment of respiratory disorders with arachidonate 15-lipoxygenase (alox15) inhibitors
MA55204A (fr) * 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
US20220347093A1 (en) 2019-09-20 2022-11-03 University Of Fukui Pharmaceutical composition
CA3161037A1 (en) 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CN117693362A (zh) * 2021-08-02 2024-03-12 甘李药业股份有限公司 含有抗il-4r抗体的稳定制剂
US20230285278A1 (en) * 2022-03-06 2023-09-14 Optinose, Inc. Methods for treating chronic rhinosinusitis
CN117368487A (zh) * 2023-09-28 2024-01-09 首都医科大学附属北京同仁医院 一种利用局部IgE预测或评估奥马珠单抗在治疗复发性鼻息肉中疗效的方法和应用
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120524A2 (en) * 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
WO2012047954A1 (en) * 2010-10-06 2012-04-12 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
US20130052190A1 (en) * 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ATE372764T1 (de) 2000-07-26 2007-09-15 Hououdou Co Ltd Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
WO2005032399A2 (en) * 2003-05-30 2005-04-14 The Regents Of The University Of California Il4 receptor antagonists for horse, dog and cat
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
WO2005085284A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 sepecific polypetides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX2010006735A (es) * 2007-12-21 2010-09-30 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
WO2009121847A2 (en) * 2008-04-02 2009-10-08 Apogenix Gmbh Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
CA2748712A1 (en) 2008-12-01 2010-06-10 Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
RU2403071C1 (ru) * 2009-09-03 2010-11-10 Логина Наталия Алексеевна Способ лечения хронических рецидивирующих воспалительных заболеваний слизистой носа и околоносовых пазух методом эндоназальной аутолимфоцитотерапии
ES2569515T3 (es) * 2010-03-16 2016-05-11 Airsonett Ab Tratamiento del asma, de la rinitis alérgica y mejora de la calidad del sueño mediante tratamiento con flujo aéreo laminar controlado por temperatura
UA111731C2 (uk) * 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
RU2469737C1 (ru) * 2011-06-28 2012-12-20 Федеральное государственное учреждение "Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи" Министерства здравоохранения и социального развития России (СПб НИИ ЛОР МИНЗДРАВСОЦРАЗВИТИЯ РОССИИ) Способ лечения хронического риносинусита
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
RS59354B1 (sr) 2013-06-21 2019-10-31 Sanofi Biotechnology Postupci lečenja nosne polipoze davanjem il-4r antagonista
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120524A2 (en) * 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
WO2012047954A1 (en) * 2010-10-06 2012-04-12 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
US20130052190A1 (en) * 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BACHERT C ET AL, "Pharmacological management of nasal polyposis", DRUGS, ADIS INTERNATIONAL LTD, NZ, (2005-01-01), vol. 65, no. 11, ISSN 0012-6667, pages 1537 - 1552 *
C. HOPKINS ET AL, "Psychometric validity of the 22-item Sinonasal Outcome Test", CLINICAL OTOLARYNGOLOGY, (2009-10-01), vol. 34, no. 5, doi:10.1111/j.1749-4486.2009.01995.x, ISSN 1749-4478, pages 447 - 454 *
D. LEZCANO-MEZA ET AL, "Interleukin (IL)-4 and to a lesser extent either IL-13 or interferon-gamma regulate the production of eotaxin-2/CCL24 in nasal polyps", ALLERGY, (2003-10-01), vol. 58, no. 10, pages 1011 - 1017 *
GEVAERT ET AL, "Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (2006-11-06), vol. 118, no. 5, pages 1133 - 1141 *
HOPKINS ET AL, "The Lund-Mackay staging system for chronic rhinosinusitis: How is it used and what does it predict?", OTOLARYNGOLOGY AND HEAD AND NECK SURGERY (2007-09-25), vol. 137, no. 4, pages 555 - 561 *
N. A. MOLFINO ET AL, "Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor", CLINICAL & EXPERIMENTAL ALLERGY, (2012-05-01), vol. 42, no. 5, pages 712 - 737 *
SCAVUZZO M C ET AL, "Inflammatory mediators and eosinophilia in atopic and non-atopic patients with nasal polyposis", BIOMEDICINE AND PHARMACOTHERAPY, ELSEVIER, FR, vol. 59, no. 6, ISSN 0753-3322, (2005-07-01), pages 323 - 329, (2005-07-01) *

Also Published As

Publication number Publication date
AU2022201336B2 (en) 2025-04-17
CY1122754T1 (el) 2021-03-12
RU2016101632A (ru) 2017-07-26
WO2014205365A1 (en) 2014-12-24
TW201534325A (zh) 2015-09-16
KR20160024916A (ko) 2016-03-07
TWI709411B (zh) 2020-11-11
IL243246B (en) 2019-09-26
PT3613432T (pt) 2025-10-29
KR20260048354A (ko) 2026-04-09
EP4663250A2 (en) 2025-12-17
TW202118513A (zh) 2021-05-16
US20150017182A1 (en) 2015-01-15
EP3010539A1 (en) 2016-04-27
SG11201509625PA (en) 2015-12-30
AU2025205430A1 (en) 2025-07-31
EP4663250A3 (en) 2026-04-08
EP3613432A1 (en) 2020-02-26
HK1222567A1 (en) 2017-07-07
HUE073368T2 (hu) 2026-01-28
PL3010539T3 (pl) 2020-01-31
AU2019261751B2 (en) 2021-11-25
US10059771B2 (en) 2018-08-28
MX2015017970A (es) 2016-11-30
CN111437387A (zh) 2020-07-24
RU2016101632A3 (enExample) 2018-05-22
SI3010539T1 (sl) 2019-11-29
CA2915839A1 (en) 2014-12-24
SG10201710557QA (en) 2018-01-30
AU2019261751A1 (en) 2019-11-28
CN105517570A (zh) 2016-04-20
RU2674680C2 (ru) 2018-12-12
CN105517570B (zh) 2020-04-07
AU2022201336A1 (en) 2022-03-24
JP2016523863A (ja) 2016-08-12
CN111437387B (zh) 2024-10-01
AU2014284235A1 (en) 2016-01-21
RS59354B1 (sr) 2019-10-31
PL3613432T3 (pl) 2026-01-19
TWI757893B (zh) 2022-03-11
JP6463351B2 (ja) 2019-01-30
KR20230066127A (ko) 2023-05-12
MX368068B (es) 2019-09-18
ES3050809T3 (en) 2025-12-23
AU2014284235B2 (en) 2019-11-21
IL243246A0 (en) 2016-03-31
KR20210132232A (ko) 2021-11-03
EP3613432B1 (en) 2025-08-06
EP3010539B1 (en) 2019-07-24
US20190040146A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
AU2022201336B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
US11214621B2 (en) Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
JP2021138743A (ja) Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法
JP2021063122A (ja) Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
HK40023224B (en) Methods for treating nasal polyposis by administering an il-4r antagonist
HK40023224A (en) Methods for treating nasal polyposis by administering an il-4r antagonist
HK1222567B (en) Methods for treating nasal polyposis by administering an il-4r antagonist
NZ752224B2 (en) Methods for treating nasal polyposis by administering an il-4r antagonist

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 24 MAR 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 24 MAR 2025